key: cord-0878704-1zyb4q8t authors: Wang, C. Y.; Hwang, K.-P.; Kuo, H.-K.; Kuo, B.-S.; Liu, H.; Hou, K.-L.; Tsai, W.-Y.; Chiu, H.-C.; Ho, Y.-H.; Cheng, J.; Wang, M.-S.; Yang, Y.-T.; Chang, P.-Y.; Shen, Y.-H.; Peng, W.-J. title: UB-612, a Multitope Universal Vaccine Eliciting a Balanced B and T Cell Immunity against SARS-CoV-2 Variants of Concern date: 2022-05-05 journal: nan DOI: 10.1101/2022.04.11.22272364 sha: 5aadea29f7af0381c2508a4ec7ee559b24e29e15 doc_id: 878704 cord_uid: 1zyb4q8t Importance. The SARS-CoV-2 non-spike structural proteins of nucleocapsid (N), membrane (M) and envelope (E) are critical in the host cell interferon response and memory T-cell immunity and have been grossly overlooked in the development of COVID vaccines. Objective. To determine the safety and immunogenicity of UB-612, a multitope vaccine containing S1-RBD-sFc protein and rationally-designed promiscuous peptides representing sequence-conserved Th and CTL epitopes on the Sarbecovirus nucleocapsid (N), membrane (M) and spike (S2) proteins. Design, setting and participants. UB-612 booster vaccination was conducted in Taiwan. A UB-612 booster dose was administered 6-8 months post-2nd dose in 1,478 vaccinees from 3,844 healthy participants (aged 18-85 years) who completed a prior placebo (saline)-controlled, randomized, observer-blind, multi-center Phase-2 primary 2-dose series (100-ug per dose; 28-day apart) of UB-612. The interim safety and immunogenicity were evaluated until 14 days post-booster. Exposure. Vaccination with a booster 3rd-dose (100-ug) of UB-612 vaccine. Main outcomes and measures. Solicited local and systemic AEs were recorded for seven days in the e-diaries of study participants, while skin allergic reactions were recorded for fourteen days. The primary immunogenicity endpoints included viral-neutralizing antibodies against live SARS-CoV-2 wild-type (WT, Wuhan strain) and live Delta variant (VNT50), and against pseudovirus WT and Omicron variant (pVNT50). The secondary immunogenicity endpoints included anti-S1-RBD IgG antibody, S1-RBD:ACE2 binding inhibition, and T-cell responses by ELISpot and Intracellular Staining. Results. No post-booster vaccine-related serious adverse events were recorded. The most common solicited adverse events were injection site pain and fatigue, mostly mild and transient. The UB-612 booster prompted a striking upsurge of neutralizing antibodies against live WT Wuhan strain (VNT50, 1,711) associated with unusually high cross-neutralization against Delta variant (VNT50, 1,282); and similarly with a strong effect against pseudovirus WT (pVNT50, 6,245) and Omicron variant (pVNT50, 1,196). Upon boosting, the lower VNT50 and pVNT50 titers of the elderly in the primary series were uplifted to the same levels as those of the young adults. The UB-612 also induced robust, durable VoC antigen-specific Th1-oriented (IFN-{gamma}+-) responses along with CD8+ T-cell (CD107a+-Granzyme B+) cytotoxicity. Conclusions and relevance. With a pronounced cross-reactive booster effect on B- and T-cell immunity, UB-612 may serve as a universal vaccine booster for comprehensive immunity enhancement against emergent VoCs. Trial registration. [ClinicalTrials.gov: NCT04773067] The devastation of the virulent Delta and the hyper-transmissible, pathologically-lesser Omicron variants (eFigure 1 in the Supplement) has declined and COVID restrictions have been lifted. While mRNA booster vaccination could reverse Omicron-induced decrease of serum neutralizing antibodies [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] and reduce rates of hospitalization and severe disease, it offers less protection against infection and mild disease. Still, Omicron can cause breakthrough infections even after the fourth vaccine jab. 11 Omicron-infected asymptomatic and mild cases shall not be treated akin to a flu. Reportedly, COVID can take a serious toll on heart health, 12 presumably to stay as a part of longhaul COVID. 13 This toll, beyond the myocarditis and pericarditis associated with mRNA vaccines, 14 encompasses a wide range of inflammatory cardiovascular disorders that elevates, depending on COVID severity, from asymptomatic, symptomatic, to acute infection cases. 12, 15, 16 Facing ever-emergent variants and long-haul COVID, new composition-updated vaccines that can prevent infection are strongly advocated. 17, 18 A universal vaccine capable of inducing durable cross-reactive viral-neutralizing antibodies along with broad T-cell immunity is desirable. Apparently, the currently authorized spike-only vaccines do not incorporate SARS-CoV-2's nonspike structure proteins of envelope (E), membrane (M) and nucleocapsid (N), the regions critically involved in the host cell interferon response and T-cell memory [19] [20] [21] [22] yet grossly overlooked in COVID vaccine development. Here we report the booster immunogenicity and safety in Phase-2 trial of UB-612, a multitope vaccine 23 (Figure 1A) containing an S1-RBD-sFc protein and rationally-designed Th and CTL epitope peptides on the Sarbecovirus nucleocapsid (N), membrane (M) and spike (S2) proteins that are sequence-conserved across all VoCs ( Figure 1B) . Booster 3rd-dose following the Phase-2 trial primary 2-dose series. We conducted a booster vaccination study (n = 1,478) which was an extension arm of the phase-2, placebo-controlled, randomized, observer-blind, multi-center primary 2-dose study (eFigure 2A in the Supplement) [ClinicalTrials.gov: NCT04773067] in Taiwan with 3,844 healthy male or female adults aged >18 to 85 years (eFigure 2B in the Supplement) who received two intramuscular doses (28 days apart) of 100 μ g UB-612 or saline placebo. 24 The objectives of the third-dose extension study was to determine the booster-induced safety and immunogenicity after unblinding, 6 to 8 months after the second dose. The Principal Investigators at the study sites agreed to conduct the study according to the specifics of the study protocol and the principles of Good Clinical Practice (GCP); and all the investigators assured accuracy and completeness of the data and analyses presented. The protocols were approved by the ethics committee at the site and all participants provided written informed consent. Full details of the booster trial design, inclusion and exclusion criteria, conduct, oversight, and statistical analysis plan are available in Supplement. Like the same vaccine product used in the Phase-1 primary and booster and the Phase-2 primary trials, UB-612 vaccine used in the present phase-2 extension booster vaccination is a multitope vaccine designed to activate both humoral and cellular responses. For SARS-CoV-2 immunogens, UB-612 combines a CHO-expressed S1-RBD-sFc fusion protein (Wuhan strain) and a mixture of synthetic T helper (Th) and cytotoxic T lymphocyte (CTL) epitope peptides, which are selected from immunodominant M, S2 and N regions known to bind to human major histocompatibility complexes (MHC) I and II. The preparation of UB-612 vaccine product consists of compounding, filtration, mixing, and filling operations. Before addition of the subunit protein S1-RBD-sFc, the individual components of the vaccine are filtered through a 0.22 micron membrane filter, including the peptide solution (2 µg/mL), CpG1, a proprietary oligonucleotide (ODN), solution (2 µg/mL), 10X protein buffer containing 40 mM Histidine, 500 mM Arginine and 0.6% Tween 80, 20% sodium chloride stock solution. After sequentially addition of each component, the S1-RBD-sFc fusion protein and peptides are formulated with components described as above to form a protein-peptide complex and then is adsorbed to aluminum phosphate (Adju-Phos®) adjuvant. The last step would be addition of water for injection containing the 2-phenoxyethanol preservative solution to make final drug product at 200 µg/mL. The UB-612 vaccine product is stored at 2 to 8 o C. Placebo used in the Phase-2 trial was sterile 0.9% normal saline. Phase-2 trial of primary and booster third-dose series. The primary safety endpoints the Phase-2 trial were to evaluate the safety and tolerability of all participants receiving study intervention from Days 1 to 365. Vital signs were assessed before and after each injection. Participants were observed for 30 minutes after each injection for changes in vital signs or any acute anaphylactic reactions. After each injection, participants had to record solicited local and systemic AEs in their self-evaluation e-diary for up to seven days while skin allergic reactions were recorded in their ediary for up to fourteen days. Safety endpoints include unsolicited AEs reported for Days 1 to Day 57 in this interim Phase-2 report. Complete details for solicited reactions are provided in the study protocols. The primary immunogenicity endpoints were the geometric mean titers (GMT) of neutralizing antibodies against SARS-CoV-2 wild-type (WT, Wuhan strain), and the post-booster effects against Omicron and Delta variant were explored as well. For WT and Delta strains, viralneutralizing antibody titers that neutralize 50% (VNT50) of live SARS-CoV-2 WT and Delta variant were measured by a cytopathic effect (CPE)-based assay using Vero-E6 (ATCC® CRL-1586) cells challenged with SARS-CoV-2-Taiwan-CDC#4 (Wuhan strain) and SARS-CoV-2- were measured by neutralization assay using HEK-293T-ACE2 cells challenged with SARS-CoV-2 pseudovirus variants expressed the spike protein of WT and Omicron BA.1variants. Assay methods are detailed below. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The secondary immunogenicity endpoints include anti-S1-RBD IgG antibody, inhibitory titers against S1-RBD:ACE2 interaction, and T-cell responses assayed by ELISpot and Determination of SARS-CoV-2 virus specific neutralization titer was to measure the neutralizing antibody titer against SARS-CoV-2 virus based on the principle of VNT50 titer (≥50% reduction of virus-induced cytopathic effects). Virus neutralization titer of a serum was defined as the reciprocal of the highest serum dilution at which 50% reduction in cytopathic effects are observed and results are calculated by the method of Reed and Muench. Neutralizing antibody titers were measured by neutralization assay using HEK-293T-ACE2 cells challenged with SARS-CoV-2 pseudovirus variants. The study was conducted in a BSL2 lab at (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Anti-S1-RBDWT binding IgG antibody by ELISA. The 96-well ELISA plates were coated with 2 µg/mL recombinant S1-RBDWT-His protein antigen (100 µL/well in coating buffer, 0.1 M sodium carbonate, pH 9.6) and incubated overnight (16 to 18 hr) at room temperature. One Bound antibodies were detected with HRP-rProtein A/G at 37 o C for 30 min, followed by six washes. Finally, 100 μ L/well of TMB (3,3',5,5'-tetramethylbenzidine) prepared in Substrate All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 5, 2022. Working Solution (citrate buffer containing hydrogen peroxide) was added and incubated at 37 o C for 15 min in the dark, and the reaction stopped by adding 100 μ L/well of H 2 SO 4, 1.0 M. Sample color developed was measured on ELISA plate reader (Molecular Device, VersaMax). UBI® EIA Titer Calculation Program was used to calculate the relative titer. The anti-S1-RBD antibody level is expressed as Log 10 of an end point dilution for a test sample (SoftMax Pro 6.5, Quadratic fitting curve, Cut-off value 0.248). in the detection of the T cell response. For the booster-series third-dose series extension study, ELISpot assays were performed using the human IFN-γ/IL-4 FluoroSpot PLUS kit (MABTECH). Aliquots of 250,000 PBMCs were plated into each well and stimulated, respectively, with 10 μ g/mL (each stimulator) of RBD-WT+Th/CTL, Th/CTL, or Th/CTL pool without UBITh1a (CoV2 peptides), and cultured in culture medium alone as negative controls for each plate for 24 hours at 37 °C with 5% CO2. The analysis was conducted according to the manufacturer's instructions. Spot-forming units (SFU) per million cells was calculated by subtracting the negative control wells. Intracellular cytokine staining and flow cytometry was used to evaluate CD4 + and CD8 + T cell responses. PBMCs were stimulated, respectively, with S1-RBD-His recombinant protein plus with Th/CTL peptide pool, Th/CTL peptide pool only, CoV2 peptides, PMA + Inonmycin (as positive controls), or cultured in culture medium alone as negative controls for 6 hours at 37°C with 5% CO 2 . Following stimulation, cells were washed and stained with viability dye for 20 minutes at room temperature, followed by surface stain for 20 minutes at room temperature, cell fixation and permeabilization with the BD cytofix/cytoperm kit (Catalog # 554714) for 20 minutes at room temperature, and then intracellular stain for 20 minutes at room temperature. Intracellular cytokine staining of IFN-γ, IL-2 and IL-4 was used to evaluate CD4 + T cell response. Intracellular cytokine staining of IFN-γ, IL-2, CD107a and Granzyme B was used to evaluate CD8 + T cell responses. Upon completion of staining, cells were analyzed in a FACSCanto II flow cytometry (BD Biosciences) using BD FACSDiva software. For the Phase-2 extension booster vaccination study, the immunogenicity results for Geometric All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 5, 2022. ; https://doi.org/10.1101/2022.04.11.22272364 doi: medRxiv preprint Mean Titer (GMT) are presented with the 95% confidence intervals. Statistical analyses were performed using SAS® Version 9.4 (SAS Institute, Cary, NC, USA) or Wilcoxon sign rank test. Spearman correlation was used to evaluate the monotonic relationship between non-normally distributed data sets. For the Phase-2 primary 2-dose series, the sample size of the trial design meets the minimum safety requirement of 3000 study participants in the vaccine group with healthy adults, as recommended by the US FDA and WHO. US Food and Drug Administration, Emergency use authorization for vaccines to prevent COVID-19: Guidance for industry, https://downloads.regulations.gov/FDA-2020-D-1137-0019/attachment_1.pdf; WHO Guidelines on clinical evaluation of vaccines: regulatory expectations, https://cdn.who.int/media/docs/default-source/prequal/vaccines/who-trs-1004-web-annex-9.pdf?sfvrsn=9c8f4704_2&download=true. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 5, 2022. ; https://doi.org/10.1101/2022.04.11.22272364 doi: medRxiv preprint moderate, 7%). The incidence of skin allergic reaction at post-booster was similar to post-dose 2 (eFigure 3B in the Supplement ). Fatigue/tiredness, muscle pain, and headaches that belonged to solicited systemic AEs were mostly mild (eFigure 3C in the Supplement ). Overall, no safety concerns were identified with UB-612. ELISpot. Vaccinees' peripheral blood mononuclear cells (PBMCs) were collected for evaluation of Interferon-γ + (IFN-γ + )-ELISpot. On Day 57 (28 days post-2 nd dose), IFN-γ SFU (Spot Forming Unit)/10 6 cells under stimulation with RBD+Th/CTL increased from the baseline 1.0 to a high 374 SFU (Figure 2A) , which maintained strong at 261 (70%) at pre-boosting (6-8 months post-2 nd dose), then rose to 444 SFU 14 days post-booster ( Figure 2D) . Similar IFN-γ profiles were observed for that stimulated with Th/CTL alone, which increased from the baseline 1.3 to a high 322 SFU on Day 57 (Figure 2A) , maintained at 182 SFU (~57%) at pre-boosting All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 5, 2022. ; https://doi.org/10.1101/2022.04.11.22272364 doi: medRxiv preprint and remained strong at 317 SFU 14 days post-booster ( Figure 2D) . Apparently, T cell responses persisted robust (60-70% of the high peak at Day 57) long over 6-8 months. These results indicate that UB-612 can induce a strong, durable IFN-γ + T cell immunity in the primary series and prompt a high level of memory recall upon boosting, and that the presence of Th/CTL peptides is essential and principally responsible for the bulk of the T cell responses, while S1-RBD plays only a minor role. Together with the insignificant low levels of the IL-4 + ELISpot responses (Figures 2B and 2E) , UB-612 vaccination at both primary series and homologous-boosting could induce pronounced Th1-predominant immunity. Along with high levels of ELISpot-based T cell responses, CD8 + T cells expressing cytotoxic markers, CD107a and Granzyme B, were observed in the primary series, accounting for a remarkable 3.6% of circulating CD8 + T cells after re-stimulation with S1-RBD+Th/CTL (Figure 2C) , which persisted at a substantial 1.8% upon booster vaccination ( Figure 2F) . Apparently, CD8 + T cell responses persisted robustly (50% of the high peak at Day 57) long over 6-8 months as well. This suggests a potential of robust cytotoxic CD8 + T responses in favor of viral clearance once infection occurs. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 5, 2022. ; https://doi.org/10.1101/2022.04.11.22272364 doi: medRxiv preprint 3D). Both age groups showed a 1.2-to 1.7-fold reduction for anti-Delta relative to anti-WT. Immunogenicity overview, antigenic and functional. Of the 871 Phase-2 study participants enrolled for the primary 2-dose series grouped for Immunogenicity investigation, 302 participants had their sera collected at pre-boosting and 14 days post-booster for antigenic assay by anti-S1-RBD IgG ELISA, and functional assays by ACE2:RBD WT binding inhibition ELISA and by neutralization against live SARS-CoV-2 wild-type Wuhan strain by cell-based CPE method (eFigure 4 in the Supplement). The results showed pronounced booster-enhanced increases in both target binding and inhibition/neutralization titers by respective 16-to 45-folds. binding inhibition (Figure 4B) . The neutralization of ACE2:RBD WT binding on ELISA correlates well with both anti-WT All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 5, 2022. ; https://doi.org/10.1101/2022.04.11.22272364 doi: medRxiv preprint ( Figure 4C ) and anti-Delta VNT 50 (Figure 4D) findings, both showed a similar high correlative Spearman r = 0.795 and 0.828, respectively. A lesser but significant correlation exists for ACE2:RBD WT binding inhibition and anti-Omicron pVNT 50 , with a Spearman r = 0.565 ( Figure 4E ). The present Phase-2 extension study (participants aged 18-85 years) has shown that UB-612 booster (the third dose) is safe and well tolerated (eFigure 3 in the Supplement), and can induce unusually high levels of cross-reactive neutralizing titers against the Delta and Omicron variants (Figure 3 ; Table 1 ) that parallel with robust, cross-reactive VoC antigen-specific T cell immunity (Figure 2 ). In particular, the booster can induce essentially the same striking degree of neutralizing strength against Delta or Omicron for both the elderly and the young adults ( Figures 3B and 3D) ; and the high viral-neutralizing titers bear only a modest ~1.0-fold (anti-Delta) to 5.0-fold (anti-Omicron) GMFR relative to WT virus (Figure 3) . Similar fold-reduction landscape is obvious in the primary and booster series in the Phase-1 trial (participants aged 20-55 years), 24 across all VoCs and other Variants of Interest (eFigures 5 and 6 in the Supplement). On safety, no concerns of vaccine-related SAE were identified (with ~4000 individuals vaccinated so far). While UB-612 has not yet been deployed geographically wide enough, its peptide-protein subunit composition containing aluminum and CpG as the adjuvants (Figure 1A) suggests that it should have a high safety profile, unlike mRNA and adeno-vectored vaccines that, upon repeat dosing, could have more severe adverse events including rare but serious adverse reactions such as myocarditis, pericarditis, Guillain-Barre syndrome, and thrombosisthrombocytopenia. 25 On cellular immunity, UB-612 can induce robust and long-lasting Th1 cell responses and prompt a high level of memory recall upon boosting. In the Phase-1 primary series, the post-2 nd dose PBMCs stimulated RBD/Th/CTL can induce high antigen-specific Th1-dominant IFN-γ + − ELISpot T cell responses at 254 SFU/10 6 cells and a long-lasting response level with ~50% retained (the pre-boosting 121 vs. peak 254) >6 months post-2 nd dose. 24 In the Phase-2 primary series, a higher SFU units of 374 post-2 nd dose and of 261 >6 months later (pre-boosting) (Figures 2A and 2D) represents even a higher 70% (261 vs. 374) retainment of T cell immunity, All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 5, 2022. ; https://doi.org/10.1101/2022.04.11.22272364 doi: medRxiv preprint with the SFU surged to 444 post-booster. The minor Th2 IL-4 + -T cell response found in the Phase-2 trial (Figures 2B and 2E ) reconfirms that observed in the Phase-1 study. 24 Evidently, the Th/CTL peptide pool (containing N, M, and S2 epitope peptides) is the principal driver of T cell immunity, with SFU units at 322 post-2 nd dose and maintained at 317 post-booster (Figures 2A and 2D) . Furthermore, a strong, durable cytotoxic (CD107a + -Granzyme B + ) activity of CD8 + T lymphocytes (CTL) accounting for a high CTL frequency at 3.6% post-2 nd dose and persists at 1.8% pre-booster (Figures 2C and 2F) indicates a 50% retainment of CTL activity more than 6 months post-2 nd dose, which maintains at the same level observed 14 days post-booster. The magnitude of the UB-612 booster-recalled T cell immunity in the present Phase-2 homologous-boosting (SFU units range ~320-450) was found to be greater than any of those produced under "mix-and-match" heterologous-boosting settings by the currently authorized mRNA, adeno-vectored, and Spike protein-based vaccines, which reported SFU/10 6 PBMC units (stimulated with spike peptide-specific to WT, Delta and Beta) to be in the range of 40 to 150. 26 That the rationally-designed UB-612 S1-RBD-sFc protein-subunit vaccine is armed with T cell immunity-promoting N (nucleocapsid), M (membrane) and S2 (spike) epitope peptides ( Figure 1B ), which are highly conserved across all VoCs, may underlie the UB-612's differentially pronounced booster-induced T cell immunity. The much more booster-enhanced T-cell immunity via UB-612 is also supported by the development of a plain T-cell vaccine containing a six-peptide backbone that, as a T-cell booster, triggered dramatic multifunctional CD4 and CD8 T-cell responses, 27 which showed notable benefits to B-cell deficient, immunocompromised patients who could not mount B-cell antibody responses. This raises the concerns over the fact that humoral antibody response has long been used as a sole metric of protective immunity, 28, 29 which lacks full understanding of human postvaccination immune responses as antibody response is generally shorter-lived than virus-reactive T cells. [30] [31] [32] Further, the SARS-CoV-2's non-spike structure proteins of envelope (E), membrane (M) and nucleocapsid (N) are the regions critically involved in the host cell interferon response and T-cell memory. [19] [20] [21] [22] These structural proteins of virus' main body when presented would fall beyond recognition by the currently authorized vaccines that based on the outer spike only, All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 5, 2022. ; https://doi.org/10.1101/2022.04.11.22272364 doi: medRxiv preprint implicating that these vaccines bear an intrinsic shortfall, 33 lacking at least N-and M-specific T cell immunity. The adaptive immune response is a major determinant of the clinical outcome, to which T cell immunity plays a central role in the control of SARS-CoV-2 infection and its importance have been underestimated thus far. 34 In fact, the non-spike viral structure proteins have long been grossly overlooked since the development of COVID vaccines. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The finding that the UB-612 induced much higher fold-increases (GMRIs) in blocking the RBD-ACE2 interaction than that by HCS ( Figure 4B) suggests that most of the antibodies in HCS may bind allosterically to the viral spike (N-or C-terminal domain of the S), rather than orthosterically to the RBD sites and may include some unwanted enhancing antibodies. This warrants further investigation including sera from re-infections and breakthrough infections from all vaccine platforms. Booster vaccination can reduce rates of hospitalization and severe diseases, yet offers less protection against infection and mild disease. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] The pathologically-lesser but hypertransmissible Omicron shall not be treated as a trivia as the coming of flu. COVID by itself can take a serious long-term toll on heart health 12 , presumably to stay as a part of long-haul COVID. 13 This toll, beyond the already known myocarditis and pericarditis associated with mRNA vaccines, 14 encompasses a cluster of inflammatory cardiovascular disorders that elevates, depending on COVID severity, from asymptomatic, symptomatic, to acute infection cases. 12, 15, 16 Facing ever-emergent variants and long-haul COVID, urgent development of compositionupdated new vaccines that can enhance immunity with sufficient magnitude, durability and breadth of virus coverage has been strongly advocated. 17, 18 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 5, 2022. ; https://doi.org/10.1101/2022.04.11.22272364 doi: medRxiv preprint As memory B and T cells are critical in secondary responses to infection, a successful vaccine must generate and maintain immunological memory, 40, 41 and to mount a rapid recall of effective humoral and cellular responses upon natural exposure or vaccine boosting. By rational design, UB-612 vaccine product has demonstrated such important vaccine features of balanced B-and T-immunity through these clinical studies. In particular, the UB-612-induced T cell immunity would comprehensively recognize spike (S2) and non-spike structure N (nucleocapsid) and M (membrane) proteins, which may boost the potential in favor of viral clearance of the infected cells regardless of mutations found in Delta and Omicron, as their mutation sites are not to overlap any of the amino acid residues on the precision-designed S2, N, and M epitope peptides that are highly conserved (or rarely mutate) across all VoCs 23 ( Figure 1B) . Presumably, the viral proteins on Omicron that are substantially conserved can serve as strong T-cell activators and induce long-lasting T-cell response 42 , which can synergize with B-cell memory for enhanced immunity. And, as non-spike structure N and M proteins fall beyond recognition by the currently authorized COVID vaccines, UB-612 may serve as a universal vaccine to fend off new Variants of Concern such as Delta, Omicron and other ever-emergent SARS-CoV-2 variants with durable and balanced B-and T-cell immunity. This study has four limitations. First, UB-612 has not yet been widely deployed geographically. Second, in-depth biomarker analysis beyond those described in this report was not conducted due to insufficient volume of blood and samples retained. Third, we used Th/CTL peptide pool for an overall in vitro assessment of immune enhancement upon booster without delineation as to which peptide contributes most to mounting T-cell immunity in each of the vaccinees, though pooling may produce synergistic effect. Fourth, the post-booster functional analyses were carried out for a short period of time, which lacks information as to how durable the B-and Tcell immune response would last. However, it is worthy to note that UB-612 multitope subunit vaccine is the first designer vaccine to elicit a potent balanced B-and T-cell immunity against SARS-CoV-2 infection. Development of a new generation of such B-T combined vaccines has been explored. Large scale efficacy trials in geographically diverse areas enrolling young and elderly with various comorbidities, in both homologous and heterologous booster studies, are undergoing to accelerate the vaccine development for its timely introduction to prevent and control COVID. The UB-612-induced T cells would comprehensively recognize spike (S2) and non-spike structure N (nucleocapsid) and M (membrane) proteins that may seed the potential favorable for viral clearance once infection occurs, regardless of mutations in the spike or non-spike protein domains on Delta and Omicron ( Figure 1B) . As non-spike structure N and M proteins fall beyond recognition by the currently authorized COVID vaccines, UB-612 may serve as a universal vaccine to ward off VoCs including Delta, Omicron and ever-emergent SARS-CoV-2 variants with a durable and balanced B-and T-cell immunity. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 5, 2022. ; https://doi.org/10.1101/2022.04.11.22272364 doi: medRxiv preprint Δ 211, L212I, ins214EPE, G339D, S371L, S373P, S375F, K417N, N440K, G446S,S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H, T547K, D614G, H655Y, N679K, P681H, N764K, D796Y, All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 5, 2022. ; https://doi.org/10.1101/2022.04.11.22272364 doi: medRxiv preprint neutralization assay for Delta variant. The viral-neutralizing antibody geometric mean titers (GMT, 95% CI) that inhibit 50% of SARS-CoV-2 wild-type Wuhan strain (WT), Omicron and Delta were measured. Statistical analysis was performed by the Student's t-test (ns, p>0.05; ****, p<0.0001). (A) The pVNT 50 titers 14 days post-booster reached at 6245 against SARS-CoV-2 WT, and at 1196 against Omicron. The 5.2-fold reduction stands for 19% preservation of neutralization titers relative the Wuhan wild type. (B) The pVNT 50 titers are presented by two age groups. (C) The VNT 50 titers 14 days post-booster reached at 1711 against live WT, and at 1282 against Delta. The 1.3-fold reduction stands for 75% preservation of neutralization titer relative to the WT. (D) The VNT 50 titers are presented by two age groups. (E) Summary of geometric mean titers (GMT) and 95% CI for plots shown in Figures (A) to (D) . All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 5, 2022. ; https://doi.org/10.1101/2022.04.11.22272364 doi: medRxiv preprint infected individuals were also included for comparative testing by two functional assays: (A) viralneutralizing titer (VNT 50 ) against live wild-type Wuhan strain (WT) by CPE method; and (B) the antibody concentration calibrated with an internal standard for ACE2:RBD WT binding inhibition by ELISA. The correlations are explored between the two function assays, i.e., ACE2:RBD WT binding inhibition ELISA and the viral-neutralizing titers against the live virus (VNT 50 for original wild-type and Delta strains) or the psuedovirus (pVNT 50 for Omicron strain). The RBD WT stands for the RBD binding protein domain bearing amino acid sequence of the original SARS-CoV-2 wild-type (WT) Wuhan strain. The correlations were explored for (C) ACE2:RBD WT inhibition vs. anti-WT VNT 50 , (D) ACE2:RBD WT inhibition vs. anti-Delta VNT 50 , and (E) ACE2:RBD WT inhibition vs. anti-Omicron pVNT 50 . The correlation coefficients were evaluated by Spearman r with 95% CI. Statistical analysis was performed with the Student's t-test (ns, p>0.05; ***, p<0.001; ****, p<0.0001). (F) Summary of geometric mean titer (GMT) and 95% CI are presented for plots as shown in Figures (A) and (B) . All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 39) , and the UB-612 in the present report ( Figure 3A ). b GMTs against WT measured at 14 or 28 days post-booster third dose. c Source of Omicron Strain for assay: FRNT/live clinical isolate; PNA/pseudovirus; PRNT recombinantly engineered with Omicron spike. d GMFR: a fold value that the post-booster anti-Omicron titer is reduced relative to the anti-WT titer. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 5, 2022. ; https://doi.org/10.1101/2022.04.11.22272364 doi: medRxiv preprint CYW, KPH, HKK, HL, YHS and WJP, were responsible for vaccine development including vaccine formulation design, protocol design and implementation of the clinical studies, acquisition and interpretation of the clinical data. HKK, KLH, JC, MSW, YTY, were responsible for assay development and validation, laboratory testing and data collection, and preparation of respective reports. CYW, YHS, HKK, HL, BSK and WJP had full access to and verified all the data in the study and take responsibility for the integrity and accuracy of the data analysis. BSK and CYW drafted and prepared the manuscript. All authors reviewed and approved the final version of the manuscript. CYW had final responsibility for the decision to submit for publication. The study protocols are provided in the Supplemental Appendices. Individual participant data will be made available when the trial is complete with data to be shared through a secure online platform. CYW is co-founder and board member of UBI, United BioPharma, and UBI Asia, and named as an inventor on a patent application covering the composition of matter of this SARS-CoV-2 vaccine (Wang CY, et al. Designer Peptides and Proteins for the detection, prevention and treatment of Coronavirus Disease, 2019 (COVID 19). WO2021/168305A1. International Publication date August 26 th , 2021. WJP is named as a co-inventor on the same patent application covering this SARS-CoV-2 vaccine. CYW, HKK, BSK, HL, YHH, KLH, JC, MSW, YTY, HCC, WYT, PYC, and WJP are employees within the UBI group. The study was funded by UBI Asia (study sponsor) and the Taiwan Centers for Disease Control, Ministry of Health and Welfare. The sponsor co-designed the trial and coordinated interactions with contract Clinical Research Organization (CRO) StatPlus staff and regulatory authorities. The CRO took charge of trial operation to meet the required standards of the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use and Good Clinical Practice guidelines. The Independent Data Monitoring Committee (IDMC) oversaw the safety data and gave recommendations to the sponsor. The interim analysis was done by the CRO StatPlus. We thank all the trial participants for their dedication to these trials; the investigation staff at China Medical University Hospital, Taipei Medical University Hospital, Far Eastern Memorial Hospital, National Cheng Kung University All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 5, 2022. ; https://doi.org/10.1101/2022.04.11.22272364 doi: medRxiv preprint Hospital, Linkou Chang Gung Memorial Hospital, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung Medical University Hospital, Tri-Service General Hospital, Taipei Veterans General Hospital, Kaohsiung Veterans General Hospital, Changhua Christian Hospital and Taichung Veterans General Hospital for their involvement in conducting the trial; and members of the IDMC for their dedication and guidance. Special thanks are also extended to the clinical associates from StatPlus, Inc and UBI Asia; the CMC task forces from both United BioPharma, Inc. and UBI Pharma, Inc; and team members at Institute of Biomedical Sciences, Academia Sinica for the live virus neutralization assay; and team members at the RNAi Core Facility, Academia Sinica for the pseudovirus neutralization assay. All health convalescent sera were supplied by Biobank at the National Health Research Institutes (NHRI), Taiwan. Finally, critical review of the manuscript by professor Chwan-Chuen King of Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, and special administrative support by Jalon Tai, Liang Kai Huang, Peter Hu and Fran Volz from the UBI group are acknowledged with gratitude. The hyper-transmissible SARS-CoV-2 Omicron variant exhibits significant antigenic change, vaccine escape and a switch in cell entry mechanism SARS-CoV-2 omicron variant neutralization after mRNA-1273 booster vaccination mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant Effectiveness of COVID-19 vaccines against the Omicron (B.1.1.529) variant of concern Booster of mRNA-1273 vaccine reduces SAR-CoV-2 Omicron escape from neutralizing antibodies Considerable escape of SARS-CoV-2 Omicron to antibody neutralization Third BNT162b2 Vaccination Neutralization of SARS-CoV-2 Omicron infection Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine-elicited human sera Improved neutralization of the SARS-CoV-2 Omicron variant after Pfizer-BioNTech BNT162b2 COVID-19 vaccine boosting Antibody binding and ACE2 binding inhibition is significantly reduced for the Omicron variant compared to all other variants of concern 4th dose COVID mRNA vaccines' immunogenicity & efficacy against omicron VOC Long-term cardiovascular outcomes of COVID-19 Pathological sequelae of long-haul COVID Myocarditis cases reported after mRNA-based covid-19 No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted Risk of myocarditis following sequential COVID-19 vaccinations by age and sex Risk of cardiovascular events after Covid-19: a double-cohort study. medRxiv preprint ICMRA COVID-19 Omicron variant workshop Covid-19: Focus should be on new vaccines rather than boosters, says WHO Omicron SARS-CoV-2 variant: Unique features and their impact on pre-existing antibodies Reduced interferon antagonism but similar drug sensitivity in Omicron variant compared to Delta variant SARS-CoV-2 isolates. bioRxiv preprint Review Devil's tools: SARS-CoV-2 antagonists against innate immunity Severe acute respiratory syndrome coronavirus Membrane (M) and Spike (S) proteins antagonize host type I Interferon Response Designer Peptides and Proteins for the detection, prevention and treatment of Coronavirus Disease, 2019 (COVID 19). WO2021/168305A1. International Publication date Potent booster effect against Delta/Omicron variants and long-lasting B-and T-immunity of UB-612, a multitope SARS-CoV-2 vaccine Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial A COVID-19 peptide vaccine for the induction of SARS-CoV-2 T cell immunity Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection Evidence for antibody as a protective correlate for COVID-19 vaccines Decline in neutralizing antibody responses, but sustained Tcell immunity, in COVID-19 patients at 7 months post-infection What are the roles of antibodies versus a durable, high quality T-cell response in protective immunity against SARS-CoV-2? Virus-specific memory CD8 T cells provide substantial protection from lethal severe acute respiratory syndrome coronavirus infection COVID: why T cell vaccines could be the key to long-term immunity. The Conversation The T cell immune response against SARS-VoV-2 Booster of mRNA-1273 strengthens SARS-CoV-2 Omicron neutralization. medRxiv preprint Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine-elicited human sera The reactogenicity and immunogenicity of a booster dose after the second dose of a protein subunit vaccine MVC-COV1901: An extension to an open-label, dose-escalation, and non-randomized phase 1 study. medRxiv preprint Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses. bioRxiv preprint Reduced sensitivity of SARS-CoV-2 Omicron variant to antibody neutralization elicited by booster vaccination Remembrance of things past: long-term B cell memory after infection and vaccination Immunological memory to SAR-CoV-2 assessed for up to 8 months after infection T cell epitopes in SARS-CoV-2 proteins are substantially conserved in the Omicron variant